1. Safety and efficacy findings from the open-label, multicenter, phase 3b, expanded treatment protocol study of ruxolitinib for treatment of patients with polycythemia vera who are resistant/intolerant to hydroxyurea and for whom no alternative treatments are available. Issue 14 (6th December 2019) Authors: Foltz, Lynda; Pica, Gian-Matteo; Zerazhi, Hacene; Van Droogenbroeck, Jan; Visanica, Sorin; Báez de la Fuente, Enrique; Leber, Brian; de Almeida, Antonio Medina; Ranta, Dana; Kiladjian, Jean-Jacques; Chrit, Linda; Kandra, Albert; Morando, Juliane; Devos, Timothy Journal: Leukemia & lymphoma Issue: Volume 60:Issue 14(2019) Page Start: 3493 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗